AVGO vs NOVT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Broadcom exhibits a dichotomy between elite operational performance and poor deterministic value metrics. While the Piotroski F-Score of 4/9 indicates stable health, the stock trades at a massive premium to its Graham Number ($44.08) and Intrinsic Value ($151.04). This valuation gap is partially justified by a very attractive PEG ratio (0.68) and strong forward P/E (19.65), suggesting high growth expectations. However, aggressive insider selling by the CEO and CFO, combined with a bearish technical trend, offsets the strong analyst 'strong_buy' consensus.
Novanta Inc. exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a very conservative debt profile (Debt/Equity 0.23). However, the company is severely overvalued based on deterministic metrics, with a current price of $128.85 dwarfing the Graham Number ($34.91) and Intrinsic Value ($11.61). While the earnings track record is stellar with consistent beats over 25 quarters, the massive trailing P/E of 87.65 and bearish insider selling by the CEO and CFO create significant valuation risk. The stock is currently a high-quality business trading at a speculative premium.
Compare Another Pair
Related Comparisons
AVGO vs NOVT: Head-to-Head Comparison
This page compares Broadcom Inc. (AVGO) and Novanta Inc. (NOVT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.